Reviews/COPD Pharmacotherapy/Mepolizumab in eosinophilic chronic obstructive pulmonary disease
Biologics · COPD-BIO-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
A large, well-run trial in people with COPD and high eosinophil counts found that adding mepolizumab on top of standard inhaler therapy lowered the yearly rate of flare-ups compared with a dummy injection [1]. A second trial in patients recently hospitalised for a flare-up showed fewer flare-ups in the same direction, but that trial missed its own main goal and the flare-up result only just reached significance [2]. A small clinic-based review of 13 patients also reported fewer flare-ups after starting the drug [10]. All three sources point the same way, so the direction of benefit is consistent, but the size of the benefit is modest and only one trial directly and clearly confirms it. Because the strongest evidence comes from a single positive trial with limited independent replication, the panel treated the claim as well supported rather than settled.
The phase 3 MATINEE trial randomised 804 patients and met its primary endpoint, with a significantly lower annualized rate of moderate or severe exacerbations on mepolizumab versus placebo (0.80 vs. 1.01 events per year; rate ratio 0.79; 95% CI 0.66 to 0.94; P=0.01), and a longer time to first exacerbation (hazard ratio 0.77; 95% CI 0.64 to 0.93; P=0.009) [1]. The phase 2b COPD-HELP trial found a directionally consistent exacerbation reduction (risk ratio 0.81; 95% CI 0.66 to 1.00), though it included the null at the upper bound and the trial's own primary endpoint of readmission or death was not met (hazard ratio 0.96; 95% CI 0.70 to 1.32; P=0.811) [2]. A retrospective single-centre cohort of 13 patients reported that median annual moderate-to-severe exacerbations fell from 4.0 to 1.0 (p=0.007) [10]. The direction of effect is unanimous across the primary data, while the magnitude is modest and confirmatory replication is thin. The contested point: The division is over whether the second RCT confirms the claim or merely points the same way: its exacerbation risk ratio of 0.81 includes the null (95% CI 0.66 to 1.00) and its primary endpoint was not met [2], so it supports direction without confirming effect. The claim therefore rests materially on the single positive pivotal trial [1], with the real-world cohort [10] hypothesis-generating only.
All 10 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from COPD Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim rests materially on a single pivotal trial [1]; the effect is modest (rate ratio 0.79, ~21% reduction) and MATINEE's downstream secondary endpoints for quality of life and symptoms were not significant.
The second RCT [2] had a negative primary endpoint (readmission/death, HR 0.96) and its exacerbation risk ratio (0.81, 95% CI 0.66-1.00) includes the null at the upper bound, so it is supportive-direction, not confirmatory.
Where it remains uncertain. The second RCT's exacerbation result was directionally consistent but non-confirmatory (risk ratio 0.81; 95% CI 0.66 to 1.00) and its primary endpoint of readmission or death was null (hazard ratio 0.96; P=0.811) [2].
Aleatory
COPD-HELP's exacerbation risk ratio (0.81; 95% CI 0.66 to 1.00) reaches the null at its upper bound, so sampling variability alone leaves the second RCT's benefit statistically indistinguishable from no effect [2].
Epistemic
Only one trial clearly met the exact exacerbation endpoint [1]; independent confirmation is not yet in the corpus [2][10].
Inferential
The cohort is retrospective, single-centre and uncontrolled, so attributing its exacerbation drop to mepolizumab rather than regression to the mean or co-treatment is an inferential leap [10].
The load-bearing papers from a corpus of 10, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal phase 3 primary-endpoint evidence that mepolizumab reduces exacerbations in eosinophilic COPD.
“The annualized rate of moderate or severe exacerbations was significantly lower with mepolizumab than with placebo (0.80 vs. 1.01 events per year; rate ratio, 0.79; 95% confidence interval [CI], 0.66 to 0.94; P = 0.01).”
Panel auditInternal validity: high · scope of inference: Patients with COPD, a history of exacerbations, blood eosinophils >=300 cells/uL on triple inhaled therapy; moderate/severe exacerbation rate over 52 to 104 weeks.Key limitations: only eosinophils >=300 cells/uL · quality-of-life and symptom secondaries not significant · GSK-funded
Second RCT showing a directionally consistent exacerbation reduction, though the CI includes the null.
“The adjusted mean number of moderate or severe exacerbations was 2.80 (95% CI, 2.36 to 3.23) with mepolizumab and 3.45 (95% CI, 2.94 to 3.95) with placebo (risk ratio 0.81; 95% CI, 0.66 to 1.00).”
Panel auditInternal validity: high · scope of inference: Patients hospitalized with an acute COPD exacerbation and blood eosinophils >=300 cells/uL in the prior 12 months; outcomes over 48 weeks from discharge.Key limitations: primary end point (readmission/death) null · exacerbation CI includes 1.00 · post-hospitalization population only · GSK-funded
Real-world cohort corroborating exacerbation reduction, but small and uncontrolled.
“Median annual moderate-to-severe exacerbations decreased from 4.0 (IQR: 1.5-10.0) to 1.0 (IQR: 0.0-2.0; p = 0.007).”
Panel auditInternal validity: low · scope of inference: COPD patients with eosinophils >300 cells/uL and frequent OCS-requiring exacerbations treated with mepolizumab for up to two years.Key limitations: n=13 · no control group · single-centre retrospective · before-after comparison only
3 of 10 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
One unambiguously positive pivotal trial on the exact outcome with directionally consistent but non-confirmatory support places this at the top of the Likely band rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent confirmatory RCT. The strongest evidence is one positive trial and both RCTs share the GSK sponsor [1][2], so a sponsor-independent replication would materially strengthen the claim. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An adequately powered, independently funded phase 3 RCT in eosinophilic COPD with annualized moderate or severe exacerbations as the primary endpoint.
Open question: Does mepolizumab reduce exacerbations in eosinophilic COPD when tested by a sponsor independent of GSK? Why it is still open: Both RCTs in the corpus are GSK-funded [1][2], so independence of the strongest evidence is untested.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19